Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
Epistemonikos ID: b5c7a7678cf66157b23e522115966cec0f7a6e4d
First added on: May 07, 2024